These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 554030)

  • 1. [Galactose and antipyrine load tests in assessing the detoxification activity of the liver].
    Maestri G; D'Amore V; Angeli E
    Minerva Dietol Gastroenterol; 1979; 25(4):399-406. PubMed ID: 554030
    [No Abstract]   [Full Text] [Related]  

  • 2. [Influence of UDPG, glutathione and vitamin B 12 therapy on various liver function indices in patients with liver cirrhosis].
    Coltorti M
    Clin Ter; 1975 Feb; 72(4):323-35. PubMed ID: 1222512
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of the changes in some laboratory parameters in liver disease patients treated with Toxepasi Complex].
    Lenzi S
    Minerva Med; 1976 Sep; 67(46):2961-74. PubMed ID: 967362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The galactose breath test. Modification of the method and comparison with galactose elimination capacity and plasma disappearance of bromsulphatein (author's transl)].
    Grimm L; Bircher J; Preisig R
    Z Gastroenterol; 1980 Jan; 18(1):45-56. PubMed ID: 7385933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function.
    Bonkovsky HL; Fiellin DA; Smith GS; Slaker DP; Simon D; Galambos JT
    Am J Gastroenterol; 1991 Sep; 86(9):1200-8. PubMed ID: 1909085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
    Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
    Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinico-statistical study of medical treatment of hyperazotemic syndromes of prevalently dysmetabolic origin].
    Taglioretti D
    Minerva Urol; 1975; 27(3):127-31. PubMed ID: 1143239
    [No Abstract]   [Full Text] [Related]  

  • 9. [Study of liver function by antipyrine clearance].
    Chrétien P; Boismare F
    LARC Med; 1983; 3(7):504-7. PubMed ID: 6645741
    [No Abstract]   [Full Text] [Related]  

  • 10. [Alcohol-induced toxic hepatitis--a "free radical" associated disease. Lowering fatality by adjuvant antioxidant therapy].
    Wenzel G; Kuklinski B; Rühlmann C; Ehrhardt D
    Z Gesamte Inn Med; 1993 Oct; 48(10):490-6. PubMed ID: 8256468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Usefulness of the determination of bile acids in the blood and antipyrine elimination in the diagnosis of minimal liver damage].
    Habior A
    Przegl Lek; 1983; 40(5):431-4. PubMed ID: 6622742
    [No Abstract]   [Full Text] [Related]  

  • 12. [The antipyrine test in occupational medicine research--evaluation of individual reproducibility and frequency distribution of half-life].
    Uhlig H; Damrau J; Skölziger R
    Z Gesamte Hyg; 1989 Feb; 35(2):82-4. PubMed ID: 2741499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alcohol abuse and glutathione administration on the circulating levels of glutathione and on antipyrine metabolism in patients with alcoholic liver cirrhosis.
    Loguercio C; Piscopo P; Guerriero C; De Girolamo V; Disalvo D; Del Vecchio Blanco C
    Scand J Clin Lab Invest; 1996 Aug; 56(5):441-7. PubMed ID: 8869667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new therapy of hepatic insufficiency. Experiments with (+)-3--cyanidanol. Its importance in the treatment of alcoholic hepatitis].
    Traissac FJ; Borg R
    Minerva Dietol Gastroenterol; 1977; 23(3):237-42. PubMed ID: 372845
    [No Abstract]   [Full Text] [Related]  

  • 15. Impaired oxidation of carbon-labeled galactose by alcoholic or diabetic liver in vivo.
    Shreeve WW
    Nuklearmedizin; 1987 Aug; 26(4):159-66. PubMed ID: 3671097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intravenous galactose overload test in acute alcoholic hepatitis].
    Vivancos J; Font J; Carbonell J; Prellezo P; Balcells A
    Rev Clin Esp; 1982 Apr; 165(1):27-9. PubMed ID: 7122933
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of metabolic efficiency of the liver in patients with psoriasis by the antipyrine test].
    Bienias L; Czarnecki M; Kaszuba A; Ruszczak Z; Kozłowska M; Bednarowicz G; Drobnik G
    Przegl Dermatol; 1990; 77(5):301-6. PubMed ID: 2270292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What is guaranteed in the therapy of alcoholic hepatitis?].
    Seitz HK; Simanowski UA
    Internist (Berl); 1993 Jan; 34(1):30-4. PubMed ID: 8440572
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmaco-metabolic activity in chronic hepatopathies: influence of treatment with UDPG].
    Okolicsànyi L; Orlando R; Lirussi F; Naccarato R; Dal Brun G
    Clin Ter; 1980 May; 93(4):431-8. PubMed ID: 6998643
    [No Abstract]   [Full Text] [Related]  

  • 20. Gut-liver axis: a new point of attack to treat chronic liver damage?
    Loguercio C; De Simone T; Federico A; Terracciano F; Tuccillo C; Di Chicco M; Cartenì M
    Am J Gastroenterol; 2002 Aug; 97(8):2144-6. PubMed ID: 12190198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.